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the psychotropic effects seen in 
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Ketamine is a valuable anaesthetic and analgesic that in recent years has gained notoriety as a 
recreational drug. Recently, ketamine has also been proposed as a novel treatment for depression and 
post-traumatic stress disorder. Beyond its anaesthetic actions, however, the effects of ketamine on 
brain activity have rarely been probed. Here we examined the cortical electroencephalography (eeG) 
response to ketamine of 12 sheep. Following ketamine administration, EEG changes were immediate 
and widespread, affecting the full extent of the EEG frequency spectrum measured (0–125 Hz). After 
recovery from sedation during which low frequency activity dominated, the EEG was characterised 
by short periods (2–3 s) of alternating low (<14 Hz) and high (>35 Hz) frequency oscillation. This 
alternating eeG rhythm phase is likely to underlie the dissociative actions of ketamine, since it is 
during this phase that ketamine users report hallucinations. At the highest intravenous dose used 
(24 mg/kg), in 5/6 sheep we observed a novel effect of ketamine, namely the complete cessation of 
cortical eeG activity. this persisted for up to several minutes, after which cortical activity resumed. this 
phenomenon is likely to explain the ‘k-hole’, a state of oblivion likened to a near death experience that 
is keenly sought by ketamine abusers.
Ketamine is a neuroactive phencyclidine derivative highly valued for its anaesthetic and analgesic properties1,2. 
Used in both medicine3 and veterinary medicine4 it has a rapid onset of action and does not cause respiratory 
depression5. Termed a ‘dissociative’ anaesthetic, it causes a characteristic anaesthesia whereby patients are cat-
atonic and do not appear to process information, yet can swallow and open their eyes3. The analgesic effects of 
ketamine occur at lower concentrations than its anaesthetic effects, and persist beyond emergence from anaes-
thesia6. Ketamine is particularly valuable as an anaesthetic and analgesic where resources are limited, such as in 
field situations and developing countries. These qualities have earned ketamine its place on the World Health 
Organisation’s essential drug list7.
The dissociative state induced by ketamine almost certainly underlies its appeal as a recreational drug8. 
Psychic sensations associated with emergence from ketamine anaesthesia are frequently reported, and because 
of this, clinical use of ketamine is largely restricted to veterinary medicine and young or elderly human patients9. 
Subjective effects include perceptual distortions, sensations of floating, vivid dreams or illusions, distortion of 
sense of time and space, and alterations in mood state and body awareness10. At a sufficiently high dose, both 
awareness of self and surroundings, and interactions with others become profoundly impaired - a state known as 
the ‘k-hole’11. Dissociation of the conscious from the physical self under the influence of ketamine is substantiated 
in psychophysiological studies in normal subjects (e.g. the false hand illusion12).
In addition to its well-described uses in the fields of anaesthesia, analgesia and drug abuse, ketamine has 
emerging applications in two other fields. Although it has not been implicated in long-term psychotic reactions 
in normal subjects, ketamine has been of interest in schizophrenia research for many years because it can pre-
cipitate the emergence of psychosis in schizophrenic patients10. It is being used to develop animal models of 
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schizophrenia13. Clinically, ketamine has attracted much recent attention following reports of its efficacy in treat-
ing psychiatric disorders, particularly depression14 and post-traumatic stress disorder15. Nevertheless, despite 
the increased interest in ketamine as a tool or treatment, little is known about its non-anaesthetic effects on brain 
function.
Here we investigated directly the effects of ketamine on cortical EEG activity using normal sheep with 
chronically-implanted subdural recording electrodes. We chose to use sheep for this study, because ketamine 
is commonly used as a large animal anaesthetic6, and its clinical (anaesthetic and analgesic) effects and phar-
macokinetics are well understood16. In recent years, sheep have been recognised as a species that is eminently 
suitable for use as pre-clinical models of human neurological disorders17,18. They have a large complex brain 
with a gyrencephalic cerebral cortex and basal ganglia that are anatomically similar to those of non-human pri-
mates. They are physically robust, and their skull anatomy is well-suited to bearing chronically implanted cranial 
devices19,20. Importantly, they are intelligent and trainable yet docile animals that are easy to manage safely in the 
laboratory20. These characteristics make them very suitable for studying the effects of neuroactive drugs, includ-
ing anaesthetics.
Over a period of several months, we explored the EEG response at different doses of ketamine, up to 24 mg/
kg (a high anaesthetic dose at the lower end of the range used recreationally). In addition to identifying the EEG 
signatures that characterize the sedative effects of ketamine, we identified two phenomena that may explain the 
psychic experiences associated with ketamine. The first is a distinct and characteristic alternating oscillatory 
state, whereby the output of the whole cortex switches between co-ordinated bursts of low and high frequency 
oscillations. The timing of this phenomenon makes it likely to underlie the dissociative state. The second, previ-
ously undescribed, phenomenon was the temporary but complete cessation of EEG cortical activity induced by 
ketamine. This phenomenon is likely to explain the ‘k-hole’ described and keenly sought by ketamine abusers11.
Results
Characteristic dose-dependent behavioural and quantitative EEG responses of sheep to keta-
mine. The behavioural response of sheep to ketamine can be separated into three distinct sequential phases 
based on the behaviour and the electromyogram (EMG)/electroocculogram (EOG) activity (Fig. 1). The first 
phase, seen shortly after delivery of ketamine, is characteristic of the well-described anaesthetic effect21. During 
this phase, voluntary movement is suppressed, as are eye movements, although the eyes remain open and they 
have intact palpebral (eye blink) reflexes. In this phase there is typically increased muscle tone22, which was 
evident in the EMG trace (see below). In the second phase, sheep are conscious and respond to gentle sensory 
stimulation such as incidental noise or movements in the visual field, but do not engage in voluntary movement. 
This corresponds to the dissociative analgesic phase. During the third phase, sheep are conscious and appear 
alert, with awake levels of EMG and EOG activity, although again they do not engage in voluntary movement. The 
duration of each of these phases is dose-dependent (data not shown).
The effect of ketamine on the EEG was similar for all recording channels (see Fig. 1A for an example 
response to 12 mg/kg ketamine). The latency to onset and the total power of the EEG response were dose- and 
route-dependent (Fig. 2; Supporting Information (SI) Table S1). Differential pharmacological effects can be seen 
clearly when separate frequency bands are analysed after drug delivery (Fig. 2A; SI Fig. S1; SI Tables S1, S2). A 
quantitative EEG (qEEG) analysis was conducted for all doses using either total power (0–125 Hz; Figs. 1B and 
2A), or classically defined frequency bands of delta (0–4 Hz), theta (4–9 Hz), alpha (9–14 Hz), beta (14–35 Hz) 
and gamma (>35 Hz). Repeated measures ANOVAs were performed for response latency and half-life in which 
different frequency bands were treated as repeated measures. Full factorial analyses incorporated the hemisphere 
and region as within subjects factors. In neither analysis were there any significant interactions involving either of 
these factors. In response to 12 mg/kg of ketamine, the earliest changes in power were seen in the low frequency 
(<14 Hz) ranges and these subsided most rapidly. By contrast, at 12 mg/kg the increased power in the gamma 
bands started significantly later (F1,10 = 32.8, P < 0.001) and persisted significantly longer than those in the lower 
frequency bands (F1,10 = 13.0, P = 0.005). Both beta and gamma power remained elevated for more than 1 h after 
administration, regardless of the route of drug delivery (SI Fig. S1, Table S1). The spectral profile of the response 
also varied according to dose, particularly in the high gamma range. The half-lives of the slow frequency band 
oscillation changes correlated closely with the duration of sedation (behavioural phase 1; SI Table S2).
Ketamine induces alternating bursts of theta-gamma oscillations that correlate with the dis-
sociative phase. In the second behavioural phase, when animals are responsive but do not engage in volun-
tary activity, the EEG was remarkable for a spectral phenomenon observable in both the raw EEG trace (Fig. 3) 
and the total power spectrograms (Figs. 1B and 3A). During this phase, a characteristic pattern of oscillations 
emerged, in which bursts of slow wave activity coupled with silence in the gamma range alternated with bursts 
of gamma oscillations with silence in the slow wave range. The bursts were irregular at first (Figs. 1B” and 3B,D) 
but regularised within a few minutes of drug delivery (Fig. 1B” and 3C,E). Once established, this pattern of 
activity took the form of ~1–2 s bursts of slow frequency oscillations alternating with ~2–3 s of gamma oscilla-
tion (Fig. 3E, SI Fig. S2). This dominated the spectral profile and persisted for >30 minutes (see for example the 
response to a 12 mg/kg dose; Fig. 1C). Waveform correlation analysis showed that bursts of oscillation in both the 
lower (delta, theta and alpha) and high frequency (gamma) ranges were synchronised in phase (SI Fig. S2). The 
bursts of low frequency oscillations were synchronised in anti-phase with the bursts of high frequency oscilla-
tions. Beta frequency oscillations (14–35 Hz) had the least tendency to occur in bursts, and there was only a weak 
correlation between beta activity and either low or high frequency burst activity.
total cessation of eeG activity after intravenous ketamine. After the highest dose of intravenous 
ketamine (24 mg/kg), a second EEG phenomenon was observed that has never been described before (Fig. 4). 
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Initially, the characteristic response to ketamine was seen. Within 2 minutes of drug delivery, however, EEG activ-
ity ceased completely in 5/6 sheep. We term this phenomenon an ‘EEG hole’. The extent and duration of this 
phenomenon varied between sheep. For 2 sheep, the interruption in the response was total and sustained for 
several minutes (Fig. 4A,E). For the other 3 sheep, the interruption in the EEG was shorter, and punctuated by 
intermittent brief periods of resumed EEG activity (Fig. 4B–D). When it occurred, the profile of the EEG hole 
Figure 1. The EEG response to ketamine. (A) Cortical EEG data were recorded via 8 electrodes positioned 
over occipital (Oc), central (Cn) and two frontal (Fr1, Fr2) areas of both left and right hemispheres (L, R). 
Electromyographic (EMG) data were recorded from electrodes in the left and right dorsal neck muscles and 
electrooculography (EOG) from periorbital electrodes. The trace shows the differential signal between the two 
electrodes for the EMG and between electrodes positioned anterior and posterior to the left eye for the EOG. 
(B) The left occipital EEG is shown as a power spectrogram. Four sections of the spectrogram are expanded in B’ 
– B””. (C) The mean (± s.e.m.) interval between low frequency bursts for each minute following intramuscular 
drug delivery is shown (n = 5 sheep). Intramuscular ketamine (12 mg/kg) delivery started at the red line in A-C. 
The key in B shows the pseudocolour range of power (mV2).
4Scientific RepoRtS |         (2020) 10:9440  | https://doi.org/10.1038/s41598-020-66023-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 2. The dose-response to ketamine. Spectrograms in A show the power across the frequency spectrum 
of the EEG (using the same pseudocolour key shown in Fig. 1B) recorded from the left frontal cortical electrode 
in a single sheep when ketamine was given (red line) intramuscularly at each of 6 doses (0.5–24 mg/kg). These 
data were collected in six separate experimental sessions, one for each dose. (B) The mean (±s.e.m.) change 
in total power across the EEG spectrum (0–125 Hz) measured in the first 15 min post-injection relative to 
that of a 10 min pre-injection baseline period is plotted against dose for sheep receiving intramuscular (N = 5; 
blue symbols) or intravenous (N = 7; red symbols) ketamine.
Figure 3. Ketamine-evoked alternation between high and low frequency EEG oscillations. EEG activity 
recorded from a single electrode (left frontal) after intramuscular delivery of 12 mg/kg ketamine (red line) is 
shown as a spectrogram (A). The key to the pseudocolour is shown in Fig. 1B. In B and C, the EEG traces are 
shown for the periods indicated by the black bars above the spectrogram in A. The position in time of the EEG 
traces in D, E are shown as black bars in B and C respectively.
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was similar for all recording electrodes across the brain (SI Fig. S3). Shortly before onset of the hole there was an 
increase in muscle tone in the EMG recorded from the neck muscles (SI Fig. S4). This was evident in each case 
when the EEG hole occurred, and was additional to the already increased EMG activity which is characteristic in 
ketamine anaesthesia22. A similar increase in tone was also apparent in EOG activity during the hole. During the 
period when the EEG holes were recorded, all sheep appeared to be deeply sedated, and there was no overt indi-
cation of any unusual brain activity. On resumption of EEG activity, a typical phase 2 response to ketamine was 
Figure 4. EEG holes are visible in spectrograms after intravenous ketamine delivery. (A–F) Spectrograms of 
EEGs recorded from 5 sheep that received i.v. ketamine (24 mg/kg; red line in A-F). For 3 of these sheep (A–C)  
the heart rate (HR) was recorded via ECG. Sheep 5 (E) received a repeated dose of ketamine in a separate 
session 3 days after the first trial (F).
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evident. That is, the pattern of activity that returned was the alternating bursts of low and high frequency activity 
in the EEG that would be expected at that time after ketamine administration. Interestingly, one of the sheep in 
which this phenomenon was seen (sheep 5, Fig. 4E) received a repeat of this dose of ketamine in a separate trial 
three days later. After the second trial, no EEG hole was seen (Fig. 4F).
The behaviour of the sheep during the EEG hole was unremarkable. They looked sedated, but otherwise 
did not show any adverse effects. In fact, for sheep 2 and 3 (Fig. 4B,C), the dropout of cortical activity was not 
observed during the recording period but was found only when the spectrograms were constructed. For some 
sheep, when recordings were made at 24 mg/kg ketamine, we added an extra recording channel to collect ECG. 
As reported elsewhere5, ketamine delivery increased the heart rate (Fig. 4A–C). In the sheep when the EEG hole 
lasted for several minutes (Fig. 4A), the heart rate fell to the pre-drug resting rate during the quiescent period. 
When cortical activity recovered, the heart rate returned to an elevated rate.
Discussion
Ketamine is highly valued for its anaesthetic and analgesic properties, yet few studies have examined in detail the 
EEG response to this drug. Here, we used sheep with chronically implanted electrodes to study the effect of keta-
mine on cortical EEG. The EEG response to ketamine showed a characterised increase in EEG power, as has been 
described previously. A high resolution analysis of the EEG, however, revealed that the changes were more com-
plex than a simple increase in power. On emergence from the sedation phase the EEG was characterised by 3–4 s 
of high power, high frequency bursts that alternated with 1–2 s of high power low frequency bursts. While the 
subjective experience of sheep cannot be determined, the clinical and psychic profile of ketamine administration 
is very well described in humans, and the timing makes it likely that this ‘oscillation of oscillations’ underlies the 
dissociative state caused by ketamine. A second striking finding was the occurrence of holes in the EEG activity 
at an intravenous (i.v.) dose of ketamine in the low recreational range23. To our knowledge, this is the first report 
of such an effect. It seems likely that the total cessation of cortical activity underpins the phenomenon known as 
the ‘k-hole’. This is a state of oblivion keenly sought by recreational users that is associated with an hallucinogenic 
experience on emergence from this state, and likened to near-death experience11.
The cortical response to ketamine of sheep appears to be similar to that of humans. Relatively few EEG studies 
have been made of humans under the influence of ketamine, and all of those have been conducted over short peri-
ods, using lower doses of ketamine, often in adjunct with other anaesthetics24,25. Nevertheless, the spectrograms 
we generated after ketamine administration in sheep resembled those of human subjects receiving intravenous 
ketamine as a general anaesthesia25,26. The EEG oscillation of oscillations we saw in the sheep also matched the 
description of the EEG during the catatonic state in ketamine-anaesthetised children24.
In this study, the different doses of ketamine were administered in the same order for each sheep. This was 
done to minimise potential hangover effects by ensuring that higher doses followed on from lower doses. This 
is a limitation of the study, as it potentially introduced a cumulative bias into the data. However, we think this is 
unlikely to be a large effect, since in the one case where the same high dose was repeated, there was desensitisa-
tion, rather than amplification, of the response to the second dose.
Better awareness of the effects of ketamine on the brain would greatly aid our understanding of its use, not 
only as an anaesthetic, analgesic or antidepressant but also as a drug of abuse. Human volunteer studies of anaes-
thetic action are invaluable, but such studies are challenging to conduct as well as risky27. Since the oscillatory 
changes we describe in the sheep have been reported in humans but not in rats or mice, rodents may not be ideal 
species for translational research into the action of ketamine. Sheep could bridge this translational gap. While not 
commonly used for neuropharmacological studies, they are a valuable model species for studying the brain19,28. 
The brain of the sheep is highly developed, with a thick and well-developed cerebral cortex similar to that seen in 
primates. We have made successful EEG recordings from sheep with subdural electrodes that have lasted more 
than 3 years. The inter-subject variability due to natural variation in brain anatomy and/or electrode placement 
is offset by high intra-subject stability. A group of 5–6 sheep is sufficiently powered to see small (<10%) changes 
in EEG responsiveness if a study is conducted longitudinally. Finally, although sheep are not currently used as 
animal models of psychiatric conditions they would make excellent models for psychiatric illnesses29, since they 
have emotional responses to the stressors that cause depression and anxiety in humans18,29.
The precise physiological mechanisms through which ketamine exerts its effects are unknown. Disruption 
of cortical network connectivity is believed to underlie ketamine anaesthesia30, and probably forms the basis for 
the hallucinogenic sensations sought by recreational users of the drug8. The ketamine-induced alternation of 
high and low frequency oscillations seen across the cortex adds a new challenge to understanding the network 
connectivity during ketamine administration, since they occur on a time scale that is below the resolution of 
most functional magnetic resonance imaging studies26. Both high and low frequency cortical oscillations are 
thought to be important for network function, with elevated power in high frequency oscillations promoting 
local connectivity and elevated power in low frequency oscillations favouring connectivity across wider corti-
cal distances31. The alternating partitioning of these two activities may explain, at least in part, the dissociative 
nature of the effects of ketamine. Although local network activity may be enhanced with increased high frequency 
oscillations, the temporal dissociation between the high and low frequency components of the EEG is likely to 
reduce functional networking between cortical regions. This may be of particular relevance to studies of schiz-
ophrenia, where disrupted cortical networks are thought to underlie, at least in part, some of the symptoms. 
Understanding how different brain regions engage and disengage is key to understanding the function of neural 
networks. Ketamine-evoked changes in the EEG provide an interesting tool for studying such networks, not only 
in the normal brain but also in neurological diseases in which cognitive and psychiatric disorder are prominent.
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Methods
Animals. The sheep used in this study were locally sourced Welsh mountain ewes (n = 5) and merino ewes 
(n = 7). All of the sheep were neurologically and genetically normal. All procedures involving the Welsh mountain 
sheep were conducted at the University of Cambridge in accordance with the UK Animals (Scientific Procedures) 
Act (1986), and the University of Cambridge ethical review board. The Welsh mountain sheep were reared in 
Cambridge, UK. At surgery their age was approximately 2 years and 3 months, and they weighed 46 ± 3.2 kg 
(SEM). All procedures involving the merino sheep were conducted at the Preclinical Imaging and Research 
Laboratories (PIRL) of the South Australian Health and Medical Research Institute (SAHMRI) and followed the 
requirements of the SAHMRI Animal Ethics Committee including the Australian Code for the Care and Use of 
Animals for Scientific Purposes (8th Edition 2013). These sheep were part of a group that included transgenic ani-
mals. Accordingly, although the sheep that were used in this study were genetically normal, all handling of these 
sheep conformed to physical containment conditions as approved by the Institutional Biosafety Committee and 
the Office of the Gene Technology Regulator (OGTR, Australia). At surgery the merino sheep were approximately 
5 years of age, and their weight was 85 ± 2.5 kg.
eeG implantation surgery. Surgical and anaesthetic procedures are described in detail in Perentos et 
al.19,20. Briefly, anaesthesia was induced using alfaxalone (3 mg/kg; Alfaxan®, Jurox, U.K., i.v.) for the Welsh 
mountain sheep, and diazepam (0.4 mg/kg) and ketamine (5 mg/kg, i.v., Ketaset, Zoetis Inc., New Jersey, USA) 
for the merino sheep. The upper airway was intubated with an endotracheal tube, and general anaesthesia was 
maintained during surgery with isoflurane in oxygen and nitrous oxide for the Welsh mountain sheep and iso-
flurane in oxygen for the merino sheep. Isoflurane was maintained at 2–3%, end-tidal CO2 at 25–30 mmHg and 
mean arterial blood pressure at 70–90 mmHg. Intravenous fluids were supplied at a rate of 5 ml/kg/h (lactated 
Ringers, Hartmann’s Solution 11 by Aquapharm). Vital functions were recorded at 5 min intervals, and blood 
gases sampled every 30 min throughout the procedure.
Once general anaesthesia was achieved, the sheep was positioned in sternal recumbency for surgery. The 
head was fixed in a stereotaxic frame (Kopf Instruments, USA). An incision was made at the midline between the 
eyes, and extended to the external occipital crest of the skull. The scalp was retracted using blunt dissection. The 
periosteum and all traces of connective tissue and fat were cleared from the skull, allowing visualisation of the 
bregma, here defined as the point of intersection of the midline scull suture and the transverse suture between 
the frontal and parietal bones. Electrode positions are defined relative to the position of the bregma. Subdural 
electrodes (3 mm diam. × 1 mm deep Ag/AgCl disc, NDimension (Science and Engineering) Ltd., Cambridge, 
UK) were implanted via craniotomies ~25 mm, ~15 mm and ~5 mm anterior, and ~10 mm posterior to bregma, 
and 10 mm lateral to the midline over both hemispheres. A reference electrode was inserted at the midline 10 mm 
posterior to bregma, and 2 ground wires were attached to the skull using stainless steel screws. Stainless steel coil 
electrodes were implanted bilaterally in the dorsal splenius muscles of the neck for recording EMG data, and 
Ag/AgCl electrodes were positioned in the inner and outer canthi of both eyes for recording the EOG. When all 
electrodes and wires were in place, a rigid cap was formed using dental acrylic containing Gentamicin (DePuy, 
Johnson & Johnson) to seal all of the components and craniotomies. Leads from all electrodes terminated at a 
multi-pin connector (Omnetics Connector Corporation, MN, USA). The connector was either exteriorised near 
the occipital crest (1 sheep), or housed in a 3D-printed polyamide (nylon) chamber (G.E. Baker (UK) Ltd) fixed 
to the skull. The chamber had a screw cap that allowed easy access to the connector post-surgery.
During surgery, a non-steroidal anti-inflammatory (carprofen) was administered. To manage possible 
post-operative infection, pain and/or inflammation, all sheep received buprenorphine at the end of surgery, and 
daily carprophen and antibiotics for three days after surgery. If necessary, additional buprenorphine was admin-
istered in the first three days according to veterinary instruction.
Recordings from the Welsh mountain sheep in this study were conducted 1–10 months post-surgery. Those 
from the merino sheep took place 6–10 months post-surgery.
electrophysiological recording. EEG data were collected wirelessly using a MCS advanced wireless sys-
tem (Multichannel Systems Gmbh, Germany). At the commencement of each recording session, each sheep was 
fitted with a 16 channel wireless head-stage (W2100-HS16). Recordings could be made simultaneously from up 
to 8 sheep at a time. Data were collected at a sampling frequency of 1 kHz on each channel.
Ketamine administration and recordings. Ketamine was delivered to individual sheep suspended in 
veterinary slings with their hooves elevated off the ground. Sheep quickly became accustomed to being restrained 
in this way, enabling a baseline recording period of 10–15 minutes preceding ketamine delivery. Recordings were 
typically made from 2–4 sheep at a time.
For the Welsh mountain sheep, ketamine was delivered intramuscularly as a single injection to the gluteus 
muscle (left or right). Merinos received ketamine intravenously via a jugular catheter. Catheters were fitted at 
least 24 h before ketamine treatment. To ensure patency, the catheters were flushed daily with heparinised saline. 
Ketamine injections were delivered between 10:00 and 16:00.
Ketamine (100 mg/ml ketamine hydrochloride solution; Ketaset, Zoetis Inc., New Jersey, USA) was admin-
istered when the sheep had remained calm in the sling for a minimum period of 15 min. All sheep received a 
separate dose of 3, 6, 12 and 24 mg/kg body weight. The doses were given in the same order to all the sheep so that 
any possible hangover effects would be similar for all animals. The order was 6, 12, 3, 24 mg/kg, with at least 2 days 
between doses. One merino sheep received a second dose of 24 mg/kg 3 days after the first. In this case, while both 
recordings are described here, only the second recording was included in subsequent statistical analysis. All of the 
Welsh mountain sheep received two additional intramuscular doses of 0.5 and 1 mg/kg ketamine.
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Drug trials were performed in separate recording sessions with a minimum of 24 h between doses. During 
recording after ketamine delivery (when two operatives were present), the sheep remained undisturbed (with a 
single observer present) for a minimum period of 1 h, but otherwise as long as was necessary. When they were 
responsive and deemed competent to stand and move normally, they were returned to their home pen. This was 
never greater than 90 min after the administration of ketamine.
electroencephalography analysis. EEG data were down-sampled to 250 Hz to promote efficient data 
processing. In subsequent analyses, EEG data were considered in terms of the contribution of identified fre-
quency bands to the overall frequency spectrum. These frequency bands reflect oscillatory activity recognised as 
delta (0–4 Hz), theta (4–9 Hz), alpha (9–14 Hz), beta (14–35 Hz) and gamma (35–125 Hz). The theta and gamma 
bands were further sub-divided into low and high theta (4–6 Hz, 6–9 Hz respectively), and into low, mid and high 
gamma (35–55 Hz, 55–85 Hz, 85–125 Hz respectively).
In an initial pre-processing stage, a global reference was generated for each sheep by computing the instanta-
neous average of all channels of EEG data. This global reference was then subtracted from each channel of EEG 
data. Thus, each EEG channel was represented as a differential signal relative to the global reference. This stage 
was conducted to minimise contamination of the EEG data by variation at the reference electrode.
The power of each oscillatory frequency in the EEG was computed using a fast Fourier transform (FFT). The 
power spectrum generated by this analysis reflects the contribution of each frequency to the total power of the 
EEG. For each recording, a temporal representation of the power spectrogram was produced in the form of a 
spectrogram. In the spectrograms, EEG power as a function of mV2 is displayed according to the colour spectrum 
in the key in Fig. 1B. In some analyses, the root mean square (RMS) of the EEG was computed. In this measure, 
the mean amplitude of the signal was computed in 1 s windows. This value was then squared and the square root 
of the resulting value calculated, thereby providing a finite positive measure of EEG activity.
Latencies of responses induced by ketamine delivery were computed for each EEG band as the time from 
start of ketamine delivery to the point at which the power in a given band increased by 100% relative to the sta-
ble pre-drug baseline. This was also computed for the change in total power across the full frequency spectrum 
(0–125 Hz).
Waveform correlation analysis was performed for certain comparisons between certain traces. This measures 
the similarity of two waveforms. Starting with the two channels aligned, each data point amplitude in the refer-
ence waveform is multiplied by each data point amplitude in the other, and summing the results. The reference 
waveform is then advanced by one sample point and the process repeated until all points in the reference channel 
are accommodated. In the resulting correlation waveform, a symmetrical upward peak implies that the two wave-
forms are synchronised and in phase, while an inverted peak implies that the two waveforms are in anti-phase.
electromyographic recordings. EOG and EMG traces were down-sampled to 250 Hz to promote efficient 
analysis. For both channels of EMG data, an average reference was computed as the average of the two EMG 
channels and all EEG channels. This average reference was then subtracted from each channel of EMG data. This 
was found to provide the most stable representation of muscle activity. A single EMG channel was then computed 
as the differential between the two average-referenced EMG channels. For the EOG data, a global reference was 
computed as the average of all four EOG channels. This average reference was then subtracted from each individ-
ual channel of EOG data. For certain analyses the EMG and EOG data were RMS transformed, as described above 
for the EEG, as a measure of absolute muscle activity.
electrocardiogram recordings. In some of the trials with intravenous ketamine the electrocardiogram 
(ECG) was recorded. These recordings were made for the merino sheep implanted in the second surgery session. 
This was achieved by attaching a single self-adhesive ECG patch to the thorax next to the left forelimb. This area 
is relatively free from wool and provides a good surface from which to acquire these data. During acquisition 
the ECG data were referenced to the same intracerebral reference as the other electrophysiological data. During 
offline processing an average reference was computed as the average of the ECG signal and all of the EEG chan-
nels, and this was subtracted from the ECG signal.
Statistical analyses. Repeated measures analyses of variance (ANOVA) were performed using SPSS (IBM 
Corp., Released 2016, IBM SPSS Statistics for Windows, Version 24.0, Armonk, NY: IBM Corp.) with different 
EEG frequency ranges entered as a within subjects variable. These analyses incorporated between subjects factors 
sufficient to account for each data instance: dose, trial, route of administration, hemisphere (left/right), brain 
region. In these analyses, data were pooled across factors which yielded no significant effect or interactions in full 
factorial analysis. Statistical significance was defined as P < 0.05.
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